- Home
- TSHA vs ECPG Comparison
TSHA vs ECPG Comparison
Compare TSHA & ECPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TSHA | ECPG |
|---|---|---|
| Founded | 2019 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2020 | 1999 |
Fundamental Metrics
Financial Performance| Metric | TSHA | ECPG |
|---|---|---|
| Price | $5.48 | $54.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 3 |
| Target Price | $10.22 | ★ $61.67 |
| AVG Volume (30 Days) | ★ 3.8M | 260.2K |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $6,310,000.00 | ★ $1,560,869,000.00 |
| Revenue This Year | N/A | $31.88 |
| Revenue Next Year | N/A | $3.57 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 17.52 |
| 52 Week Low | $1.05 | $26.45 |
| 52 Week High | $5.95 | $56.67 |
Technical Indicators
Market Signals| Indicator | TSHA | ECPG |
|---|---|---|
| Relative Strength Index (RSI) | 59.06 | 65.19 |
| Support Level | $5.22 | $53.02 |
| Resistance Level | $5.95 | $54.92 |
| Average True Range (ATR) | 0.34 | 1.66 |
| MACD | 0.05 | -0.15 |
| Stochastic Oscillator | 75.26 | 65.34 |
Price Performance
Historical ComparisonAbout TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About ECPG Encore Capital Group Inc
Encore Capital Group Inc is an international specialty finance company. It provides debt recovery solutions for consumers and property owners across a broad range of financial assets. The company purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals as the consumers repay their obligations and work toward financial recovery. Encore has only a reportable segment portfolio purchasing and recovery.